Bile Acid Metabolism Subtypes Reveal Immune Markers in CRC
2026-06-26
Feng et al. (2026) introduce a novel molecular subtyping of colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key markers linked to immune dysfunction and prognosis. Their integrative transcriptomic and clinical analyses offer new perspectives for biomarker-driven patient stratification and immune microenvironment assessment in CRC.
Degarelix Acetate: Precision GnRH Receptor Antagonist Workfl
2026-06-25
Degarelix acetate empowers researchers with rapid, reproducible hormone suppression in both in vitro and in vivo models, setting a new standard for prostate cancer and pituitary regulation studies. Its selectivity and validated performance streamline experimental design and troubleshooting, offering clear advantages over classical GnRH agonists.
Recombinant Human IL-15: Precision Immune Modulation Workflo
2026-06-25
Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) unlocks robust, reproducible T and NK cell activation and proliferation for advanced immunological assays. This guide delivers workflow refinements, troubleshooting insights, and cross-disciplinary context—bridging neuroimmune research and practical immune modulation.
GSK126 EZH2 Inhibitor: Optimizing Cancer Epigenetics Researc
2026-06-24
GSK126, a potent and selective EZH2 inhibitor from APExBIO, empowers researchers to dissect PRC2-mediated gene silencing in cancer models with nanomolar precision. This article delivers actionable workflows, troubleshooting strategies, and practical protocol enhancements for translational oncology and epigenetics labs.
Aztreonam: Protocol Enhancements for Gram-Negative Resistanc
2026-06-23
Aztreonam stands out as a synthetic monocyclic β-lactam antibiotic, uniquely targeting Gram-negative aerobic bacteria and enabling robust resistance and metabolism research. This article details optimized experimental workflows, troubleshooting tactics, and protocol advances that leverage Aztreonam’s solubility, stability, and precise inhibitory profile for translational microbiology and pharmacology.
BIIE 0246: Decoding Y2R Antagonism in the Adipose-Neural Axi
2026-06-23
Discover the advanced role of BIIE 0246 as a neuropeptide Y Y2 receptor antagonist in dissecting adipose-neural interactions and feeding behavior modulation. This article delivers original insights and practical assay guidance beyond standard applications.
FAISL lncRNA Blocks Calpain-2 FAK Cleavage in TNBC Progressi
2026-06-22
This study uncovers how the long non-coding RNA FAISL stabilizes focal adhesion kinase (FAK) by directly inhibiting calpain-2-mediated proteolysis, thereby promoting triple negative breast cancer (TNBC) progression and metastasis. These findings clarify a crucial regulatory axis and suggest new therapeutic targets in aggressive breast cancer.
Lysosomal β-Galactosidase Staining Kit in Senescence Researc
2026-06-22
Uncover the scientific power of the Lysosomal β-Galactosidase Staining Kit for precise lysosomal enzyme activity analysis in cellular senescence studies. This article offers advanced insights and practical guidance for optimizing control staining, interpreting results, and integrating recent mechanistic advances in oncology research.
PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Cancer Resea
2026-06-21
PF-562271 HCl stands out as a highly selective, nanomolar-potent FAK/Pyk2 inhibitor for dissecting tumor growth and metastasis mechanisms. Its robust performance and workflow-friendly characteristics empower advanced cancer biology experiments, with optimized protocols supporting reproducibility across cell signaling and microenvironment studies.
CCT007093: PPM1D Inhibitor Unlocks P38 MAPK Pathway Insights
2026-06-20
CCT007093 from APExBIO stands out as a selective PPM1D inhibitor, enabling precise dissection of P38 MAPK signaling in cancer and acute kidney injury models. This article delivers actionable workflows, troubleshooting strategies, and translational insights, ensuring robust, reproducible results for researchers targeting the PPM1D signaling pathway.
Beclin1 Deficiency Mitigates DOX-Induced Liver Injury via Fe
2026-06-19
This study uncovers a novel regulatory axis in doxorubicin-induced liver injury, demonstrating that Beclin1 deficiency lessens hepatic damage by inhibiting both ferroptosis and autophagy. These insights clarify the interplay between autophagic and ferroptotic pathways and highlight malondialdehyde quantification as a critical readout for oxidative stress.
EdU Imaging Kits (Cy5): Precision S-Phase DNA Synthesis Dete
2026-06-19
EdU Imaging Kits (Cy5) enable precise, reliable detection of cell proliferation by directly quantifying DNA synthesis during the S-phase. This 5-ethynyl-2'-deoxyuridine imaging kit outperforms traditional BrdU assays in sensitivity and preservation of cell structure, making it ideal for high-content fluorescence microscopy and flow cytometry applications.
Axitinib (AG 013736): Quantitative Assay Design & Functional
2026-06-18
Explore the unique quantitative and functional insights of Axitinib (AG 013736) in advanced angiogenesis and cancer biology research. This article offers a deep dive into assay design, mechanistic evidence, and critical distinctions in drug response evaluation for superior experimental outcomes.
K+ Channel Blockade Alters Renal Blood Flow in Septic Rats
2026-06-18
This study investigates how blocking ATP-sensitive and calcium-activated potassium channels modifies the renal vascular response to vasoactive drugs in septic rats. Findings reveal that selective channel inhibition exacerbates renal blood flow reduction when combined with norepinephrine or phenylephrine, highlighting the complex role of K+ channels in septic vascular dysfunction and potential implications for research into sepsis-induced kidney injury.
3-Deazaadenosine Hydrochloride: Precision in HSC Fibrosis As
2026-06-17
3-Deazaadenosine hydrochloride enables targeted modulation of methylation in hepatic stellate cell (HSC) activation, offering unmatched selectivity and reproducibility in fibrosis workflows. APExBIO’s high-purity SAHH inhibitor empowers advanced mechanistic dissection and troubleshooting, elevating both inflammation and cell proliferation research beyond generic solutions.
461 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page